Sky Century Investment (SKYI) Income from Continuing Operations (2024 - 2026)
Sky Century Investment's (SKYI) quarterly Income from Continuing Operations came in at 4347.0 in Q2 2026, up 66.68% year-on-year from 2607.96 in Q2 2025, and down 173.52% on a QoQ basis from 5913.0 in Q1 2026.
Sky Century Investment (SKYI) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 3 years of Income from Continuing Operations data on file, last reported at 4347.0 in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 66.68% year-over-year to 4347.0 in Q2 2026; TTM through May 2026 was 62452.0, a 34.97% increase from a year earlier, with the FY2025 full-year figure at 117225.0, down 60.76% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 4347.0, down from 5913.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for SKYI reached as high as 5913.0 in Q1 2026 and fell as low as 41628.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 20853.7 across 3 years, with a median of 20677.5 in 2024.
- Across the five-year window, Income from Continuing Operations plunged 145.07% in 2025 and surged 122.11% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 41628.0 in 2024, then jumped by 32.23% to 28213.0 in 2025, then surged by 84.59% to 4347.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 4347.0 in Q2 2026, 5913.0 in Q1 2026, and 28213.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | -4,347.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -4,347.00 |
| Feb 28, 2026 | 5,913.00 |
| Nov 30, 2025 | -28,213.00 |
| Aug 31, 2025 | -35,805.00 |
| May 31, 2025 | -13,047.00 |
| Feb 28, 2025 | -26,745.00 |
| Nov 30, 2024 | -41,628.00 |
| Aug 31, 2024 | -14,610.00 |
| May 31, 2024 | -14,149.00 |
| Feb 29, 2024 | -35,906.00 |